47 results on '"Pierce, Evangeline"'
Search Results
2. Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
3. A Checklist to Aid in Identifying Patients with Atopic Dermatitis Who are Candidates for Systemic Therapy
4. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis
5. 517 - Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis
6. 493 - Lebrikizumab does not impact vaccine-induced immune responses: results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis
7. 497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis
8. Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
9. 494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
10. Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis
11. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis
12. Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year
13. Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis
14. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
15. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials
16. Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
17. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
18. The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata
19. Burden of adult atopic dermatitis and unmet needs with existing therapies
20. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial
21. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
22. Understanding Flares in Pediatric and Adolescent Patients with Moderate or Severe Atopic Dermatitis: A Real-world Study in the United States and Europe
23. Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
24. Impact Of Day-to-Day Sleep Disruption on The Burden of Disease In Moderate-severe Adult Atopic Dermatitis Patients
25. 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
26. Long‐term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate‐to‐severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE‐AD7
27. Prevalence, incidence and relative risk of cardiovascular disease risk factors in adults with atopic dermatitis: A systematic review
28. Baricitinib 2 mg for the treatment of atopic dermatitis in North America : Long‐term efficacy and patient‐reported outcomes
29. 33006 Long-term improvement of patient-reported outcomes in adult patients with atopic dermatitis treated with baricitinib in the US and Canada
30. 33273 Impact of atopic dermatitis lesion locations on patient burden: A real-world study
31. 33536 Impact of day-to-day sleep disruption on the burden of disease in moderate-severe adult atopic dermatitis patients
32. 33639 Symptomatic burden and treatment needs in adult atopic dermatitis
33. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
34. Onset of Symptom Relief Reported in Daily Diaries in Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)
35. Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis
36. The direct and indirect costs of adult atopic dermatitis
37. 25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5
38. 26670 The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in a baricitinib phase 3 study, BREEZE-AD5
39. A Qualitative Analysis of Provider Notes of Atopic Dermatitis-Related Visits Using Natural Language Processing Methods
40. Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
41. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
42. Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral
43. 15058 The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis
44. Treatment of adult atopic dermatitis patients according to disease characteristics and demographics
45. Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
46. Prenatal depression screening among a diverse healthy start population.
47. Is macrolide and beta-lactam combination therapy associated with early clinical stability or 30 day mortality in hospitalized patients with pneumonia? An assessment of confounding by indication.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.